GPR35; DRD4; ADRA2C; ADRA2A; | |
TSHR; NPSR1; CXCR1; NMUR2; | |
ALPL; RECQL; TDP1; PLA2G1B; BLM; CTDSP1; P4HB; TERT; PKM; PIK3R1; GLO1; HPGD; PGD; MPO; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; HSD17B2; ALOX12; GFER; AKR1B10; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; APEX1; POLB; CD38; | |
PTPN1; DUSP3; | |
ACHE; GAA; | |
BCL2; | |
AKT1; MET; CAMK2B; GSK3B; CSNK2A1; DAPK1; NEK2; FLT3; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; DYRK1A; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; INSR; PLK4; CDK1; MAPK1; MAPK14; EGFR; ERBB2; PIM1; NUAK1; ALK; FYN; AXL; NEK6; KDR; PLK1; PKN1; | |
CA12; CA14; CA7; CA3; CA5B; CA5A; CA1; CA9; CA13; CA4; CA6; CA2; | |
AR; | |
ESRRA; | |
PPARA; | |
KDM4E; | |
MAOA; ALOX5; TYR; XDH; | |
CASP7; CASP1; | |
MMP13; MMP12; MMP3; MMP2; MMP14; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
DNMT1; | |
FUT7; | |
ABCC1; ABCB1; ABCG2; | |
SLC22A6; SLCO1B1; SLCO1B3; | |
SMAD3; LMNA; MAPT; HBB; RAB9A; NPC1; APP; TTR; HSPA1A; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP14 | Matrix metalloproteinase 14 | P50281 | CHEMBL3869 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.058E-12 | 1.589E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.304E-11 | 3.931E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.277E-10 | 2.419E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, MPO, NOX4, SRC |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.381E-10 | 2.516E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, XDH |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 4.529E-10 | 4.587E-08 | ADRA2A, AURKB, BCL2, CA2, CA7, CD38, EGFR, FYN, HIF1A, KDR, MAPK1, MAPK14, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, SRC, TNKS, TNKS2 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.534E-09 | 1.440E-07 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, SLCO1B1, SLCO1B3, TEK, TSHR |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.675E-09 | 1.558E-07 | AXL, EGFR, ERBB2, FYN, INSR, MET, NOX4, PDGFRB, PIK3R1, PTK2, SRC, TEK |
MF | GO:0005488; binding | GO:0019901; protein kinase binding | 2.277E-09 | 2.075E-07 | ADRA2A, AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, HIF1A, MAPK1, MAPK14, NEK6, PARP1, PDGFRB, PIK3R1, PKN1, PLK1, PTK2, PTPN1, SMAD3, SRC, TP53 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.047E-09 | 2.675E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 5.801E-09 | 4.821E-07 | AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, AURKA, AURKB, BCL2, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDK1, CSNK2A1, DUSP3, EPHB4, ERBB2, FLT3, FYN, GFER, GLO1, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, LMNA, MAP3K8, MAPK1, MAPK14, MAPT, MMP14, NEK2, NEK6, NFKB1, PGD, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PLK1, PLK4, PTK2, PTPN1, PYGL, RAB9A, SMAD3, SMN1, SMN2, SRC, STAT6, TNKS, TNKS2, TP53, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.975E-09 | 6.456E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.465E-08 | 1.144E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.615E-08 | 1.252E-06 | AURKB, CA2, CA7, EGFR, HIF1A, MAPK1, MAPK14, NEK2, NPC1, NPSR1, PLA2G1B, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.689E-08 | 1.304E-06 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
MF | Unclassified; | GO:0032403; protein complex binding | 2.686E-08 | 2.003E-06 | ACHE, ADRA2A, APEX1, EGFR, FLT3, FYN, IGF1R, INSR, KDR, MMP12, MMP13, MMP14, MMP9, P4HB, PIK3R1, PKM, PLK1, PPARA, PTPN1, SMAD3, SRC, TLR2, TSHR |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 3.682E-08 | 2.699E-06 | ADRA2A, ADRA2C, AHR, AURKA, AXL, BCL2, BRAF, EGFR, ERBB2, HIF1A, NFKB1, P4HB, PIK3R1, SMAD3, TLR2, TP53, TTR, TYR |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.517E-08 | 3.246E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 5.262E-08 | 3.732E-06 | APP, CDK1, EGFR, MAPK1, MAPK14, PARP1, PIK3R1, SMAD3, TLR2 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.682E-08 | 3.991E-06 | EGFR, FYN, IGF1R, INSR, KDR, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 6.626E-08 | 4.608E-06 | AXL, FLT4, FYN, KDR, MAPK14, PIK3R1, PTK2, SRC |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 6.645E-08 | 4.608E-06 | AXL, FYN, IGF1R, INSR, PDGFRB, PIK3R1 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 7.395E-08 | 5.064E-06 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.017E-07 | 6.772E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.044E-07 | 6.887E-06 | HIF1A, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.280E-07 | 8.295E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.689E-07 | 1.627E-05 | HIF1A, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 3.340E-07 | 1.960E-05 | APP, BACE1, EGFR, FYN, INSR, KDR, MAPK1, NPC1, SLC22A6, SRC, STAT6, TEK, TLR2 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 3.728E-07 | 2.176E-05 | EGFR, ERBB2, INSR, KDR |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.219E-07 | 2.415E-05 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKA, AURKB, BCL2, BLM, CAMK2B, CASP7, CDK1, CSNK2A1, CTDSP1, DNMT1, DUSP3, DYRK1A, ESRRA, GSK3B, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, MAPK1, MAPK14, NEK2, NEK6, NFKB1, NUAK1, PARP1, PIM1, PKN1, PLK1, POLB, PPARA, RECQL, SMAD3, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.620E-07 | 3.162E-05 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 6.772E-07 | 3.801E-05 | AKT1, AURKA, AURKB, DYRK1A, MAPK1, MAPK14 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 8.721E-07 | 4.747E-05 | AKT1, AURKA, AURKB, BLM, CSNK2A1, DYRK1A, L3MBTL1, MAPK14, NUAK1, TP53 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 9.700E-07 | 5.241E-05 | AKR1B1, AKT1, CD38, DNMT1, EGFR, HSD17B2, KDR, MMP2, PDGFRB, SLC22A6, SRC, TLR2, TP53 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.165E-06 | 6.159E-05 | AKT1, BCL2, HIF1A, LMNA, P4HB, SRC, TERT, TP53 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.340E-06 | 7.012E-05 | ALK, CDK1, DRD4, INSR, MAPK1, MAPK14, PKN1, PLA2G1B, PTPN1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.439E-06 | 7.443E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.785E-06 | 9.038E-05 | ADRA2A, ADRA2C, AKT1, AXL, FYN, MAPK1, PIK3R1, SRC |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.801E-06 | 9.099E-05 | ALOX15, EGFR, ERBB2, PDGFRB, PPARA, SMAD3, TP53 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.902E-06 | 9.543E-05 | AKT1, BCL2, MAPT, PTPN1, TP53 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 2.144E-06 | 1.066E-04 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.423E-06 | 1.191E-04 | ALOX15, APP, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 2.725E-06 | 1.319E-04 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 3.229E-06 | 1.522E-04 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 3.542E-06 | 1.655E-04 | AKT1, APEX1, BCL2, BRAF, CA5A, CA5B, CASP1, CDK1, CYP1A1, CYP1B1, FYN, GFER, GSK3B, HSD17B10, HSPA1A, MAOA, MAPK1, MAPK14, MMP2, MPO, NFKB1, NOX4, PARP1, PKM, SRC, TP53 |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 3.606E-06 | 1.681E-04 | ADRA2C, AKT1, APP, AR, AURKA, AXL, BCL2, BRAF, CA2, CAMK2B, FYN, HIF1A, KDR, MAPK14, MAPT, MMP14, NFKB1, PARP1, SMAD3, TERT, TLR2 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.804E-06 | 1.751E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 3.899E-06 | 1.788E-04 | FLT3, FLT4, KDR, PDGFRB |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.098E-06 | 1.871E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.169E-06 | 2.313E-04 | ALOX12, ALOX15, ALOX5, HPGD |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 5.194E-06 | 2.313E-04 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 5.194E-06 | 2.313E-04 | AKT1, BCL2, FYN, HSPA1A, TERT |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 5.194E-06 | 2.313E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 5.859E-06 | 2.567E-04 | ABCG2, ADRA2A, AHR, APP, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3, TLR2, TSHR |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 6.238E-06 | 2.701E-04 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.376E-06 | 2.749E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 6.952E-06 | 2.963E-04 | BCL2, NOX4, PDGFRB, SRC, TERT |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 7.396E-06 | 3.121E-04 | AKT1, BCL2, HIF1A, HSPA1A, MMP9, PTPN1, SRC |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 8.080E-06 | 3.377E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, BCL2, BLM, CAMK2B, FLT3, FLT4, HPGD, MAPT, NFKB1, PYGL, SLC22A6, SMAD3, TERT, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 8.151E-06 | 3.394E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 1.012E-05 | 4.118E-04 | FLT3, FYN, KDR, PDGFRB, PTK2, TEK |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.012E-05 | 4.118E-04 | EGFR, ERBB2, FYN, MET, PDGFRB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.341E-05 | 5.261E-04 | AKT1, EGFR, HBB, INSR, SMAD3 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.419E-05 | 5.526E-04 | FLT3, FLT4, KDR |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 1.419E-05 | 5.526E-04 | ABCB1, ABCC1, ABCG2 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.651E-05 | 6.329E-04 | CYP1A1, PDGFRB, POLB, TP53 |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 1.660E-05 | 6.340E-04 | ALOX5, CXCR1, GAA, HBB, HSPA1A, MAPK1, MAPK14, MMP9, MPO, NFKB1, PKM, PYGL, TLR2, TTR |
MF | Unclassified; | GO:0004872; receptor activity | 1.657E-05 | 6.340E-04 | ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, ESRRA, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, PDGFRB, PPARA, TEK, TLR2, TSHR |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.702E-05 | 6.422E-04 | AKT1, INSR, MAPK14, PIK3R1, TERT |
BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 1.903E-05 | 7.106E-04 | AURKA, BCL2, HSPA1A, MAPK1, PIK3R1, PLK1, SMAD3, SRC, TERT, USP2 |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.006E-05 | 7.416E-04 | HIF1A, SMAD3, TERT, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.006E-05 | 7.416E-04 | HPGD, MMP2, MMP9, TERT |
BP | GO:0051179; localization | GO:1905477; positive regulation of protein localization to membrane | 2.057E-05 | 7.580E-04 | AKT1, BCL2, EGFR, ERBB2, FYN, PIK3R1, TP53 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.257E-05 | 8.219E-04 | ADRA2A, ADRA2C, DRD4 |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 2.589E-05 | 9.271E-04 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 2.711E-05 | 9.661E-04 | AURKA, GSK3B, HSPA1A, MAPT, MET, NEK2, PLK1, PLK4 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.806E-05 | 9.950E-04 | BCL2, CA2, CA7, FYN, KDR, NPSR1, PARP1, PLA2G1B, SRC |
BP | GO:0008152; metabolic process | GO:0009895; negative regulation of catabolic process | 3.038E-05 | 1.069E-03 | ADRA2A, AKT1, BCL2, EGFR, FYN, MAPK14, MET, NPC1, PPARA, SMAD3 |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.367E-05 | 1.168E-03 | APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 3.367E-05 | 1.168E-03 | BLM, RECQL, TP53 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 3.453E-05 | 1.193E-03 | AKR1B1, APEX1, BCL2, BLM, GAA, HIF1A, NOX4, PARP1, SRC, TERT |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 3.594E-05 | 1.236E-03 | APP, BRAF, CA2, CA7, DRD4, EGFR, MAPK1 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 4.674E-05 | 1.560E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 4.674E-05 | 1.560E-03 | APP, GSK3B, IGF1R, PARP1 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 4.784E-05 | 1.578E-03 | ABCB1, CA2, CA7 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 4.784E-05 | 1.578E-03 | ABCB1, ABCC1, ABCG2 |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 4.777E-05 | 1.578E-03 | AURKA, AURKB, CDK1, PLK1, POLB |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 5.232E-05 | 1.706E-03 | BCL2, NOX4, PARP1, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 5.422E-05 | 1.759E-03 | AURKA, AURKB, CDK1, PKN1 |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 5.472E-05 | 1.773E-03 | AR, BCL2, CA2, CA9, EGFR, HIF1A, MET, MMP14, SMAD3, SRC |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 5.597E-05 | 1.796E-03 | EGFR, NMUR2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.597E-05 | 1.796E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.597E-05 | 1.796E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.597E-05 | 1.796E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 5.721E-05 | 1.824E-03 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
CC | GO:0044464; cell part | GO:0009986; cell surface | 5.970E-05 | 1.900E-03 | ABCB1, ACHE, APP, AXL, BACE1, CA4, CD38, EGFR, MET, PDGFRB, PLA2G1B, TEK, TLR2, TSHR |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 6.058E-05 | 1.920E-03 | ADRA2A, ADRA2C, ALK, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, PDGFRB, TEK, TSHR |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 6.344E-05 | 2.003E-03 | ABCC1, ADRA2A, ADRA2C, ALK, APP, AXL, BACE1, DRD4, EPHB4, FLT3, FLT4, GPR35, IGF1R, INSR, KDR, MET, MMP14, NPC1, NPSR1, SLC22A6, SLCO1B1, SLCO1B3, TEK, TLR2, TSHR |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 6.541E-05 | 2.061E-03 | IGF1R, INSR, PIK3R1 |
BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 7.566E-05 | 2.340E-03 | AHR, DYRK1A, EGFR, GSK3B, PPARA, TP53, USP2 |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 7.994E-05 | 2.459E-03 | ADRA2C, ALOX12, APP, AXL, BCL2, CD38, CTDSP1, EGFR, ERBB2, GPR35, GSK3B, HIF1A, LMNA, NFKB1, PIK3R1, PTK2, SMAD3, TEK, TERT, TLR2, XDH |
BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 8.097E-05 | 2.483E-03 | AURKB, CSNK2A1, NEK2, NEK6, PLK1, TNKS |
BP | GO:0050896; response to stimulus | GO:0031663; lipopolysaccharide-mediated signaling pathway | 8.187E-05 | 2.490E-03 | AKT1, MAPK1, MAPK14, TLR2 |
CC | GO:0043226; organelle | GO:0051233; spindle midzone | 8.187E-05 | 2.490E-03 | APP, AURKA, AURKB, PLK1 |
BP | GO:0032502; developmental process | GO:0022603; regulation of anatomical structure morphogenesis | 8.302E-05 | 2.521E-03 | ALOX12, AR, BCL2, BRAF, CAMK2B, CYP1B1, ERBB2, FLT4, FYN, HIF1A, KDR, MAPK14, MAPT, PIM1, PKN1, PTK2, SRC, TEK, TERT, XDH |
BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 8.584E-05 | 2.603E-03 | APEX1, APP, BRAF, NOX4, TEK, TYR |
BP | GO:0065007; biological regulation | GO:0051092; positive regulation of NF-kappaB transcription factor activity | 9.081E-05 | 2.746E-03 | ALK, APP, AR, HSPA1A, NFKB1, PLA2G1B, TLR2 |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 9.303E-05 | 2.806E-03 | EPHB4, GAA, INSR, PTK2 |
BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 1.019E-04 | 3.026E-03 | EGFR, ERBB2, FYN, MET, PDGFRB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.052E-04 | 3.109E-03 | AKT1, INSR, PPARA, SRC |
BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.052E-04 | 3.109E-03 | ADRA2C, AKT1, CD38, EGFR |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.084E-04 | 3.193E-03 | ADRA2A, BCL2, CD38, PARP1, SRC, TNKS, TNKS2 |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.085E-04 | 3.194E-03 | ACHE, AKR1B1, APEX1, APP, AURKA, CA4, EGFR, ERBB2, HSPA1A, NOX4, NPC1, SRC, TNKS2, TYR, USP2 |
BP | GO:0002376; immune system process | GO:0050778; positive regulation of immune response | 1.089E-04 | 3.199E-03 | BCL2, BRAF, CD38, FYN, HSPA1A, MAPK1, MAPK14, MMP12, MMP2, NFKB1, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, TLR2 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.121E-04 | 3.269E-03 | CYP19A1, HSD17B1, HSD17B2 |
CC | GO:0044421; extracellular region part | GO:0070062; extracellular exosome | 1.190E-04 | 3.445E-03 | ABCB1, ABCC1, AKR1B1, AKR1B10, ALDH1A1, ALK, ALOX12, ALPL, APP, AXL, CA1, CA2, CA4, CA6, CD38, CDK1, CTDSP1, DUSP3, EPHB4, GAA, GLO1, HBB, HPGD, HSPA1A, INSR, MAPK1, MAPK14, MMP9, MPO, NPC1, P4HB, PDGFRB, PGD, PKM, PYGL, RAB9A, SLC22A6, SRC, TTR |
BP | GO:0009987; cellular process | GO:0010389; regulation of G2/M transition of mitotic cell cycle | 1.272E-04 | 3.634E-03 | APP, AURKA, AURKB, BLM, CDK1, NEK2, PLK1, PLK4 |
BP | GO:0008152; metabolic process | GO:0006081; cellular aldehyde metabolic process | 1.279E-04 | 3.646E-03 | AKR1B10, ALDH1A1, CYP1B1, GLO1, PGD |
BP | GO:0008152; metabolic process | GO:0010629; negative regulation of gene expression | 1.442E-04 | 4.084E-03 | AHR, AKT1, APP, AR, AURKB, CD38, DAPK1, DNMT1, DYRK1A, ESRRA, FYN, HIF1A, HSPA1A, KDR, L3MBTL1, MAPT, MMP12, NFKB1, PARP1, PLK1, PPARA, SMAD3, SRC, STAT6, TERT, TP53, USP2, XDH |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 1.489E-04 | 4.188E-03 | CA2, CD38, EGFR, SRC |
BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 1.580E-04 | 4.440E-03 | AKR1B1, AKT1, ALDH1A1, FUT7, GAA, MAPK14, PKM |
BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 1.660E-04 | 4.605E-03 | AKT1, CA2, PDGFRB, SRC |
BP | GO:0009987; cellular process | GO:0045742; positive regulation of epidermal growth factor receptor signaling pathway | 1.660E-04 | 4.605E-03 | ADRA2A, ADRA2C, AKT1, MMP9 |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.671E-04 | 4.605E-03 | APP, TLR2 |
BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 1.671E-04 | 4.605E-03 | ABCB1, ABCC1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.671E-04 | 4.605E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.671E-04 | 4.605E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.671E-04 | 4.605E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.671E-04 | 4.605E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.671E-04 | 4.605E-03 | ALOX12, ALOX15 |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.765E-04 | 4.851E-03 | TERT, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.819E-04 | 4.963E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.844E-04 | 5.025E-03 | AKT1, CASP1, CASP7, PTK2 |
BP | Unclassified; | GO:0006461; protein complex assembly | 1.967E-04 | 5.327E-03 | ACHE, AR, BLM, BRAF, CDK1, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, MAPT, PKM, PTK2, SLC22A6, SMAD3, SRC, TEK, TERT, TP53 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 2.003E-04 | 5.406E-03 | ADRA2A, AKT1, HIF1A, INSR, NOX4, PIK3R1, PYGL |
BP | GO:0009987; cellular process | GO:0038128; ERBB2 signaling pathway | 2.043E-04 | 5.485E-03 | EGFR, ERBB2, PIK3R1, SRC |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.160E-04 | 5.770E-03 | BCL2, PTK2, SRC |
BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 2.160E-04 | 5.770E-03 | BCL2, EGFR, HIF1A |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.217E-04 | 5.887E-03 | CA2, MAPK1, MMP14, PDGFRB, TEK |
BP | GO:0032501; multicellular organismal process | GO:0050767; regulation of neurogenesis | 2.362E-04 | 6.215E-03 | ADRA2C, AKT1, APP, BCL2, BRAF, CAMK2B, CDK1, CTDSP1, FYN, GSK3B, HIF1A, MAPT, PTK2, TERT, TLR2 |
BP | GO:0009987; cellular process | GO:0071383; cellular response to steroid hormone stimulus | 2.363E-04 | 6.215E-03 | AR, EGFR, FLT3, NPC1, SRC |
BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 2.430E-04 | 6.361E-03 | CA3, CDK1, FYN, HPGD, POLB, TP53 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 2.430E-04 | 6.361E-03 | AHR, AR, GSK3B, PPARA, SMAD3, TP53 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.608E-04 | 6.753E-03 | CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 2.847E-04 | 7.319E-03 | FYN, GSK3B, MAPT, PARP1, TP53 |
BP | GO:0032502; developmental process | GO:0048538; thymus development | 2.995E-04 | 7.662E-03 | BCL2, BRAF, MAPK1, TYR |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 3.002E-04 | 7.672E-03 | AR, CDK1, HIF1A, POLB, SMAD3, TNKS, TNKS2, TP53, USP2 |
BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 3.024E-04 | 7.710E-03 | CAMK2B, GSK3B, HSPA1A, MAPK1, MAPT |
BP | GO:0008152; metabolic process | GO:0018958; phenol-containing compound metabolic process | 3.024E-04 | 7.710E-03 | AKR1B1, BCL2, DRD4, MAOA, TYR |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 3.113E-04 | 7.918E-03 | AKT1, HIF1A, TERT |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 3.275E-04 | 8.244E-03 | AKT1, HIF1A, KDR, MAPK14 |
BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 3.275E-04 | 8.244E-03 | CDK1, LMNA, NEK6, PLK1 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 3.275E-04 | 8.244E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.325E-04 | 8.274E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.325E-04 | 8.274E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.325E-04 | 8.274E-03 | TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 3.325E-04 | 8.274E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.325E-04 | 8.274E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 3.325E-04 | 8.274E-03 | APP, INSR |
MF | GO:0005488; binding | GO:0005497; androgen binding | 3.325E-04 | 8.274E-03 | ALDH1A1, AR |
BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 3.352E-04 | 8.332E-03 | ADRA2A, ADRA2C, FLT3, FYN, PTPN1, SRC, TP53 |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 3.483E-04 | 8.608E-03 | CD38, CYP1A2, EGFR, ESRRA, HPGD, PDGFRB |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 3.574E-04 | 8.783E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 3.604E-04 | 8.828E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 3.604E-04 | 8.828E-03 | AKR1B1, AKT1, AR, EGFR, SRC |
BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 3.815E-04 | 9.252E-03 | CASP1, CASP7, MAPT, SMAD3, XDH |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 3.815E-04 | 9.252E-03 | ALPL, CYP1A1, EGFR, TP53, TYR |
BP | Unclassified; | GO:0042993; positive regulation of transcription factor import into nucleus | 3.891E-04 | 9.404E-03 | APP, PIK3R1, SMAD3, TLR2 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.984E-24 | 2.174E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.909E-18 | 2.626E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.155E-16 | 3.871E-14 | ABCB1, ABCC1, ABCG2, AKT1, ALK, AURKA, AURKB, AXL, BLM, BRAF, CAMK2B, CDK1, CSNK2A1, DAPK1, DYRK1A, EGFR, EPHB4, ERBB2, FLT3, FLT4, FYN, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MAPK1, MAPK14, MET, NEK2, NEK6, NUAK1, PDGFRB, PIM1, PKM, PKN1, PLK1, PLK4, PTK2, PYGL, RECQL, SRC, TEK, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.485E-15 | 4.255E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.262E-13 | 5.380E-11 | AR, BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DNMT1, ESRRA, GLO1, L3MBTL1, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PARP1, PPARA, PTPN1, SMAD3, TNKS, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.953E-23 | 1.622E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.248E-15 | 8.413E-13 | CAMK2B; SRC; MMP2; BRAF; PIK3R1; MAPK14; HIF1A; MMP9; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.260E-13 | 6.426E-12 | PDGFRB; GSK3B; SMAD3; FLT3; MMP1; DAPK1; MMP2; BRAF; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PTK2; IGF1R; AR; ERBB2; BCL2; AKT1; MAPK1; MET; TP53 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.768E-14 | 5.282E-12 | PDGFRB; GSK3B; BRAF; PIK3R1; EGFR; NFKB1; IGF1R; AR; ERBB2; BCL2; AKT1; MAPK1; TP53 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.712E-13 | 1.106E-11 | MMP1; DAPK1; SRC; MMP2; ERBB2; MAPK1; BRAF; MMP9; TP53; EGFR |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.591E-12 | 5.243E-11 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PIK3R1; PTK2; EGFR; IGF1R; ERBB2; KDR; BCL2; AKT1; MAPK1; FYN; MET |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.799E-12 | 5.243E-11 | PDGFRB; PKM; FLT3; ERBB2; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.562E-11 | 1.135E-09 | PDGFRB; GSK3B; INSR; FLT4; PIK3R1; PTK2; EGFR; NFKB1; IGF1R; KDR; BCL2; AKT1; MAPK1; TEK; PKN1; TP53; MET; TLR2 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.605E-12 | 1.429E-10 | PTPN1; SMAD3; CSNK2A1; SRC; INSR; ERBB2; MAPK1; FYN; MET; EGFR; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.157E-11 | 2.622E-10 | CAMK2B; INSR; ERBB2; BCL2; AKT1; MAPK1; TEK; PIK3R1; HIF1A; EGFR; NFKB1; IGF1R |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.441E-10 | 8.236E-09 | PDGFRB; SRC; INSR; FLT4; BRAF; PIK3R1; MAPK14; EGFR; IGF1R; KDR; AKT1; MAPK1; TEK; MET |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.755E-10 | 1.531E-08 | PDGFRB; CAMK2B; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.291E-10 | 1.239E-08 | CAMK2B; GSK3B; SRC; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; EGFR; PTK2 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.123E-09 | 1.636E-08 | SMAD3; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.191E-09 | 2.793E-08 | PDGFRB; AKT1; MAPK1; BRAF; PIK3R1; TP53; MET; EGFR; IGF1R |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.517E-09 | 3.879E-08 | PLK4; SMAD3; INSR; PLK1; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; EGFR; IGF1R |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.135E-08 | 9.647E-08 | PDGFRB; PLA2G1B; INSR; FLT4; PIK3R1; EGFR; NFKB1; IGF1R; KDR; AKT1; MAPK1; TEK; MET |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.419E-09 | 7.207E-08 | MMP14; CASP7; MMP3; AKT1; MAPK1; MAP3K8; PIK3R1; MAPK14; MMP9; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.412E-09 | 8.348E-08 | SMAD3; SRC; BCL2; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.609E-09 | 3.131E-08 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.655E-09 | 6.788E-08 | ALK; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.843E-09 | 8.200E-08 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; BRAF; ALOX12; CYP2C19 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.613E-09 | 3.879E-08 | GSK3B; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.567E-08 | 2.695E-07 | PDGFRB; DNMT1; ABCC1; ABCB1; MMP9; EGFR; NFKB1; ERBB2; PIM1; BCL2; CYP1B1; MAPK1; TP53; MET |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.727E-08 | 1.355E-07 | CAMK2B; GSK3B; BCL2; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; TP53; NFKB1 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.110E-08 | 3.595E-07 | SMAD3; MMP2; PIM1; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.554E-08 | 4.313E-07 | DNMT1; PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; FUT7; HSD17B1; ALOX5; HSD17B2; CD38; XDH; GAA; PGD; TYR; CYP2C9; CYP2C8; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPL |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.633E-08 | 3.376E-07 | GSK3B; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; PPARA; TP53; EGFR; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.527E-08 | 1.246E-07 | GSK3B; SMAD3; BCL2; AKT1; MAPK1; BRAF; PIK3R1; TP53 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 5.730E-08 | 3.897E-07 | GSK3B; CSNK2A1; AKT1; RAB9A; FYN; PIK3R1; TP53; NFKB1; HSPA1A; TLR2 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.243E-09 | 1.690E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.643E-07 | 1.498E-06 | GSK3B; CSNK2A1; BCL2; CDK1; AKT1; CD38; PIK3R1; MAPK14; TP53; NFKB1; HSPA1A |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.971E-07 | 1.206E-06 | ALOX5; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; HSPA1A; TLR2 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.595E-07 | 1.880E-06 | PDGFRB; DUSP3; AKT1; MAPK1; BRAF; MAP3K8; MAPT; MAPK14; TP53; EGFR; NFKB1; HSPA1A |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.278E-07 | 1.327E-06 | ABCC1; BCL2; AKT1; MAPK1; FYN; PIK3R1; MAPK14; TP53; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.438E-07 | 4.003E-06 | CASP7; PARP1; LMNA; BCL2; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.707E-07 | 2.911E-06 | PLK1; CDK1; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; IGF1R |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.778E-07 | 1.133E-06 | FLT3; PIM1; AKT1; MAPK1; BRAF; PIK3R1; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.171E-07 | 3.071E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; EGFR; HSPA1A |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.846E-07 | 3.811E-06 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.006E-07 | 4.101E-06 | GSK3B; AKT1; MAPK1; MAP3K8; FYN; PIK3R1; MAPK14; NFKB1 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.863E-07 | 1.579E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; MAPK14; PTK2 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.289E-06 | 5.593E-06 | PTPN1; GSK3B; INSR; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.009E-07 | 1.206E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 9.047E-07 | 4.101E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 9.159E-06 | 3.525E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; BRAF; PIK3R1; NFKB1; PTK2 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.208E-07 | 1.722E-06 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 4.432E-06 | 1.845E-05 | CAMK2B; MMP14; SRC; MMP2; MAPK1; MAPK14; EGFR |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.946E-07 | 4.411E-06 | SMAD3; AKT1; MAPK1; BRAF; PIK3R1; TP53; NFKB1 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 7.955E-06 | 3.182E-05 | PTPN1; GSK3B; INSR; AKT1; MAPK1; BRAF; PIK3R1; PYGL |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.031E-05 | 3.825E-05 | PDGFRB; CXCR1; INSR; AKT1; MAPK1; FYN; PIK3R1; EGFR |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.649E-05 | 5.606E-05 | CAMK2B; ACHE; BCL2; AKT1; MAPK1; FYN; PIK3R1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.219E-05 | 4.288E-05 | AKT1; MAPK1; MAP3K8; PIK3R1; MAPK14; NFKB1; TLR2 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.076E-05 | 3.857E-05 | SMAD3; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; TLR2 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.198E-06 | 9.342E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 4.212E-05 | 1.343E-04 | GSK3B; CASP1; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; HSPA1A |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.208E-05 | 1.055E-04 | CAMK2B; AR; PLK1; CDK1; MAPK1; AURKA; IGF1R |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.454E-05 | 8.206E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 4.751E-05 | 1.491E-04 | CAMK2B; SRC; BCL2; AKT1; MAPK1; MAPK14; NFKB1; TLR2 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.135E-04 | 3.173E-04 | PDGFRB; POLB; GSK3B; SMAD3; TERT; AKT1; PIK3R1; TP53; NFKB1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 8.008E-05 | 2.368E-04 | GSK3B; SMAD3; AKT1; MAPK1; PIK3R1; MAPK14; IGF1R |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.315E-06 | 3.262E-05 | AKT1; MAPK1; BRAF; PIK3R1; MET; HIF1A |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.038E-04 | 2.942E-04 | CAMK2B; AKT1; MAPK1; BRAF; PIK3R1; PPARA; NFKB1; TSHR |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.275E-04 | 3.469E-04 | POLB; PKM; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.177E-04 | 3.245E-04 | GSK3B; CASP7; INSR; AKT1; PIK3R1; PPARA; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.604E-06 | 3.103E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.310E-05 | 1.921E-04 | INSR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 9.898E-06 | 3.739E-05 | CXCR1; SRC; MAPK14; MET; EGFR; NFKB1 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 9.422E-05 | 2.746E-04 | PDGFRB; AKT1; MAPK1; PIK3R1; HIF1A; EGFR |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.821E-05 | 1.237E-04 | BCL2; AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.276E-04 | 5.731E-04 | BACE1; APP; GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.078E-05 | 3.857E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.654E-04 | 6.602E-04 | SRC; AKT1; MAPK1; FYN; PIK3R1; MAPK14 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 6.148E-04 | 1.378E-03 | SMAD3; CXCR1; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.272E-05 | 4.399E-05 | SLCO1B1; ABCB1; CA2; SLCO1B3; CYP3A4; ABCG2 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 3.583E-04 | 8.702E-04 | CAMK2B; GSK3B; MAOA; AKT1; MAPK14; DRD4 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.052E-04 | 9.525E-04 | AKT1; MAPK1; FYN; PIK3R1; MAPK14; NFKB1 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.295E-04 | 8.099E-04 | GSK3B; MAPK1; FYN; MET; PTK2; EPHB4 |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 9.665E-04 | 2.033E-03 | PDGFRB; SRC; MAPK1; BRAF; PIK3R1; PTK2; EGFR |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 7.417E-04 | 1.610E-03 | CAMK2B; BCL2; AKT1; MAPK1; PIK3R1; MAPK14 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.042E-03 | 2.169E-03 | CAMK2B; SRC; CD38; MAPK1; PIK3R1; EGFR |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 3.246E-03 | 5.965E-03 | PDGFRB; CXCR1; FLT3; FLT4; KDR; MET; EGFR |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.385E-03 | 2.743E-03 | INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.572E-02 | 2.526E-02 | GPR35; NMUR2; ADRA2C; ADRA2A; DRD4; TSHR |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.889E-04 | 4.941E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 7.390E-04 | 1.610E-03 | CAMK2B; SRC; ALOX12; PIK3R1; MAPK14 |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.012E-02 | 1.706E-02 | PDGFRB; CAMK2B; ERBB2; CD38; EGFR |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.130E-02 | 1.889E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.932E-03 | 1.034E-02 | PIM1; BCL2; AKT1; STAT6; PIK3R1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.785E-03 | 6.894E-03 | CAMK2B; GSK3B; SMAD3; CSNK2A1; TP53 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 8.472E-04 | 1.800E-03 | CAMK2B; PKM; AKT1; PYGL; PPARA |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.350E-04 | 3.623E-04 | AKT1; MAPK1; FYN; PIK3R1; MAPK14 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.407E-05 | 2.222E-04 | AKT1; MAPK1; BRAF; PIK3R1; HIF1A |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.689E-02 | 2.671E-02 | MAPK1; BRAF; FYN; PIK3R1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.697E-03 | 3.328E-03 | MMP2; PIK3R1; MAPK14; MMP9; PTK2 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.010E-04 | 2.903E-04 | INSR; AKT1; PIK3R1; HSPA1A; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.109E-03 | 3.984E-03 | GSK3B; SMAD3; PLK1; CDK1; TP53 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 4.517E-04 | 1.047E-03 | PDGFRB; SRC; CDK1; MAPK1; EGFR |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.272E-02 | 2.076E-02 | INSR; AKT1; PIK3R1; IGF1R |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 4.062E-04 | 9.525E-04 | CASP1; MAPK1; PKN1; MAPK14; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.889E-04 | 4.941E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 3.017E-02 | 4.627E-02 | AKT1; MAPK1; PIK3R1 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 3.271E-02 | 4.979E-02 | CA2; PLA2G1B; CD38 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.146E-04 | 5.472E-04 | CASP7; CASP1; MAPK1; MAPK14; NFKB1 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 6.071E-03 | 1.041E-02 | CAMK2B; GSK3B; MAPK1; TYR |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 6.071E-03 | 1.041E-02 | PIK3R1; NFKB1; PTK2; TLR2 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.699E-03 | 8.336E-03 | CSNK2A1; PARP1; BCL2; NFKB1 |
hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 4.182E-03 | 7.483E-03 | MMP1; MMP3; TEK; TLR2 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 4.857E-05 | 1.501E-04 | CASP7; CASP1; NFKB1; TLR2; HSPA1A |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.496E-03 | 4.670E-03 | SRC; PIK3R1; MET; PTK2 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.958E-03 | 3.768E-03 | MAPK1; MAPK14; NFKB1; TLR2 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.434E-02 | 2.322E-02 | AKT1; PPARA; NFKB1 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.224E-02 | 2.014E-02 | CAMK2B; MAPK1; BRAF |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 7.266E-04 | 1.610E-03 | INSR; AKT1; PIK3R1; TSHR |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 9.448E-03 | 1.606E-02 | MAPK1; BRAF; IGF1R |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.274E-03 | 2.572E-03 | SRC; MAPK1; MAPK14; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.274E-03 | 2.572E-03 | SMAD3; STAT6; NFKB1; TLR2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 7.770E-04 | 1.669E-03 | CASP1; MAPK1; MAPK14; NFKB1 |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 5.084E-04 | 1.165E-03 | BCL2; CASP1; MAPK14; TP53 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 4.026E-04 | 9.525E-04 | PKM; INSR; MAPK1; PIK3R1 |
hsa05144 | Malaria_Homo sapiens_hsa05144 | 5.389E-03 | 9.478E-03 | HBB; MET; TLR2 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.978E-04 | 5.107E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.977E-03 | 7.180E-03 | ABCC1; ABCB1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.818E-03 | 5.226E-03 | INSR; MAPK1; PIK3R1 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.657E-02 | 4.137E-02 | MAOA; TYR |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.800E-02 | 4.327E-02 | AKR1B10; AKR1B1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.246E-02 | 3.525E-02 | AKR1B10; AKR1B1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.627E-02 | 2.594E-02 | MAPK1; EGFR |
hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 2.061E-03 | 3.930E-03 | MAPK1; FYN; HSPA1A |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.188E-03 | 2.448E-03 | MAPK1; BRAF; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.313E-03 | 2.626E-03 | AKR1B10; GAA; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.736E-03 | 3.374E-03 | POLB; PARP1; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.195E-02 | 1.982E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.146E-04 | 1.166E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; DNMT1; DNMT1; TEK; KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2 |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5; MAPK14; EGFR; BCL2 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; TERT; FLT3; FLT4; EGFR; ERBB2; BCL2; PLK1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; TEK; MAPK14; MMP1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; DNMT1; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; AXL; KDR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR; ERBB2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; INSR; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C; APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; ALOX5 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; AURKA; PLK1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; MMP12; MMP12; ALOX5; MAPK14 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; ABCB1; MMP2; EGFR; EGFR; PARP1; KDR; KDR; KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; BRAF |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; TERT; FLT3; MMP2; EGFR; KDR; PLK1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; INSR; PKM; MMP13; ACHE; IGF1R; CDK1; ADRA2C; ADRA2A |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; ERBB2; KDR; KDR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; INSR; PTPN1; PDGFRB; GSK3B |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; TSHR; KDR |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; DNMT1; DNMT1; AURKB; AURKA; TP53; TP53; PLK1 |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; EGFR; EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB; APP |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PTPN1; PTPN1; NFKB1 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT; SRC; IGF1R; CD38; BCL2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
C00-D49: Neoplasms | Breast cancer | C50 | AR; TERT; INSR; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; BCL2; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; BRAF; EGFR; PARP1; TYR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; ERBB2; TP53; KDR |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3; EGFR |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; KDR |
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; CD38; TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; INSR |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9 |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
NA: NA | HIV infections | NA | AHR |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; FLT4; EGFR |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; CA9; HIF1A; EGFR; ERBB2; BCL2; PLK1 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; MMP12; ALOX5; ALOX5; ERBB2; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; ALOX5 |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; CASP1; MMP3; ALOX5; MAPK14; TYR; MMP1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | MAPK14 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; PTK2; BRAF; AURKA; TP53 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; BCL2 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; EGFR; EGFR; EGFR; TP53; KDR; KDR |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; TLR2; PKM; ABCB1; FLT3; CA9; MMP2; MMP14; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; HIF1A; MAPK1; MMP9; EGFR; ERBB2; TP53; KDR; KDR; KDR; PLK1; PLK1 |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; TLR2; CSNK2A1; ABCB1; CA1; FLT3; FLT3; CA9; MMP2; ACHE; DNMT1; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; GSK3B; HIF1A; CDK1; MAPK1; MAPK14; MMP9; NFKB1; EGFR; ERBB2; ERBB2; PIM1; PARP1; CD38; BCL2; BCL2; TP53; KDR; PLK1; APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
NA: NA | Inflammatory diseases | NA | MAPK14 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; MMP13; MMP12; ALOX5; MAPK14 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
NA: NA | GIST | NA | FLT3 |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; KDR; APP |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; SRC; EGFR; EGFR; ERBB2 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |